Starling Oncology director exits 2027 race, steps down from board leadership

This is a governance transition, not an operating update. Brad Hively plans to leave Starling Oncology’s board after the 2027 annual meeting and has already stepped down as vice chairman and from all board committees.

The immediate change is broader than a future director retirement. Hively is expected to remain a director until the annual meeting, but no longer holds the vice-chair role or committee assignments. 〔0〕

Relative to expectations, there is no clean beat-or-miss benchmark. The filing gives no indication of an operational, financial, or strategic impact, and explicitly says the decision was not caused by a disagreement with the company. 〔1〕

Net read: a new but currently neutral board-change disclosure. The material item to monitor is who replaces Hively as vice chairman and on the committees, particularly Compliance, before the 2027 annual meeting.